Shell Asset Management CO Mirati Therapeutics, Inc. Transaction History

Shell Asset Management CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $16,837 - $25,014	-401 Reduced 23.15%	1,331 $78,000
Q3 2023 Nov 08, 2023	SELL	$27.8 - $45.35 $778 - $1,269	-28 Reduced 1.59%	1,732 $75,000
Q2 2023 Jul 28, 2023	SELL	$36.13 - $49.49 $361 - $494	-10 Reduced 0.56%	1,760 $64,000
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $219 - $325	-6 Reduced 0.34%	1,770 $66,000
Q4 2022 Feb 07, 2023	SELL	$41.27 - $98.62 $14,815 - $35,404	-359 Reduced 16.81%	1,776 $80,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $33,260 - $48,465	-559 Reduced 20.75%	2,135 $149,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $195 - $443	5 Added 0.19%	2,694 $181,000
Q1 2022 May 04, 2022	SELL	$75.82 - $150.97 $30,176 - $60,086	-398 Reduced 12.89%	2,689 $221,000
Q4 2021 Feb 09, 2022	BUY	$132.01 - $190.29 $2,904 - $4,186	22 Added 0.72%	3,087 $453,000
Q3 2021 Nov 04, 2021	SELL	$132.13 - $177.45 $18,498 - $24,843	-140 Reduced 4.37%	3,065 $542,000
Q2 2021 Aug 12, 2021	BUY	$144.0 - $179.73 $461,520 - $576,034	3,205 New	3,205 $518,000
Q1 2021 May 10, 2021	SELL	$158.92 - $221.61 $232,499 - $324,215	-1,463 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$72.01 - $120.39 $105,350 - $176,130	1,463 New	1,463 $167,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.